Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash from Operations (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Cash from Operations data on record, last reported at 4878000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 23.13% year-over-year to 4878000.0; the TTM value through Dec 2025 reached 18919000.0, up 18.07%, while the annual FY2025 figure was 18919000.0, 18.07% up from the prior year.
  • Cash from Operations reached 4878000.0 in Q4 2025 per LCTX's latest filing, down from 3616000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 21904000.0 in Q1 2022 and bottomed at 11242000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 4526000.0, with a median of 5783000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: skyrocketed 395.04% in 2022, then tumbled 151.32% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 7424000.0 in 2021, then fell by 11.84% to 8303000.0 in 2022, then rose by 27.51% to 6019000.0 in 2023, then fell by 5.43% to 6346000.0 in 2024, then rose by 23.13% to 4878000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 4878000.0 in Q4 2025, 3616000.0 in Q3 2025, and 5539000.0 in Q2 2025.